NeonMind Biosciences Inc. (CSE: NEON) (“NeonMind“), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia where he was previously Professor of Internal Medicine, and he has extensive experience in the design of clinical trials for treatments for eating disorders. He has also been appointed to NeonMind’s Board of Advisors.
It may seem counterintuitive that psilocybin could help treat a condition like obesity, but I have found it (and other psychedelics) to be extremely helpful in overcoming my own issues with binge eating in the past. Going into a psychedelic experience with the intention to heal from an eating disorder is just as valid as healing from depression, anxiety, or PTSD, although it hasn’t been formally studied very much yet. I’m very interested what the body of research in this area will show in five years’ time and will be following it closely here on Think Wilder.